R&D JP Morgan 2023 – Alexandre LeVert Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs
Events Partner Content 4th Annual Cell Engager Summit | May 24-26 | Boston, MA Learn from the pioneers of immunotherapy
Events Partner Content Cell-Mediated Therapies for Infectious Disease Summit Cell-Mediated Therapies for Infectious Disease Summit
Views & Analysis How T-cell therapy saved my life Judy Perkins’ stage 4 cancer was eradicated after she joined a clinical trial for T-cell therapy.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.